Orgovyx™ (relugolix tablets; Myovant Sciences) is now available through authorized specialty distributors for the treatment of adult patients with advanced prostate cancer.
Orgovyx is an oral nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to pituitary GnRH receptors, thereby, reducing the release of luteinizing hormone and follicle-stimulating hormone, and consequently testosterone. The approval was based on results from the HERO trial, an open-label study in men with advanced prostate cancer requiring at least 1 year of androgen deprivation therapy and defined as biochemical (PSA) or clinical relapse following local primary intervention, newly diagnosed castration-sensitive metastatic disease, or advanced localized disease.
To assist eligible patients in obtaining Orgovyx, the Company is offering the Orgovyx Support Program. The program provides insurance verifications, prior authorizations, copay support, free trial for up to 2 months of therapy, and patient assistance for qualifying uninsured patients.
Orgovyx is supplied as 120mg tablets of relugolix in 30-count bottles and 9-count blister packs.
For more information visit orgovyx.com.
Myovant Sciences announces U.S. availability of Orgovyx™ for the treatment of advanced prostate cancer. [press release]. Basel, Switzerland: Myovant Sciences; January 5, 2021.
This article originally appeared on MPR